LFG
CTMX icon

Larson Financial Group’s CytomX Therapeutics CTMX Stock Holding History

Larson Financial Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Hold
300
– – ﹤0.01% 3272
2026
Q1 		$1.41K Buy
+300
New +$1.52K ﹤0.01% 3064

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Larson Financial Group's CTMX Position: Q2 2026 in Review

Larson Financial Group held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 300 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

Larson Financial Group first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.41K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Larson Financial Group held 300 shares of CytomX Therapeutics worth $1.13K as of Q2 2026.
  • Larson Financial Group left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3272 holding.
  • Larson Financial Group first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Larson Financial Group's CytomX Therapeutics position peaked at $1.41K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.